PTCT
Ptc Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.27 / 10
Netural
Analyst coverage is overwhelmingly bullish (100% Buy) with strong conviction, yet historical win rate is only 0.0% on recent predictions, hinting at potential over-optimism. Fund flow is rated 'good' (7.74/10) with negative short-term trends across block, small, medium, large, and extra-large flows, implying institutions may be trimming positions even as retail inflows persist.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionBarclays
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for PTCT?
- PTCT holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.27/10 (Netural).
